508 related articles for article (PubMed ID: 16451258)
21. Randomized clinical study for comparative evaluation of fourth-generation fluoroquinolones with the combination of fortified antibiotics in the treatment of bacterial corneal ulcers.
Shah VM; Tandon R; Satpathy G; Nayak N; Chawla B; Agarwal T; Sharma N; Titiyal JS; Vajpayee RB
Cornea; 2010 Jul; 29(7):751-7. PubMed ID: 20489580
[TBL] [Abstract][Full Text] [Related]
22. A study of bacterial isolates from corneal specimens and their antibiotic resistance profile.
Begum NN; Al-Khattaf AS; Al-Mansouri SM; Yeboah EA; Kambal AM
Saudi Med J; 2006 Jan; 27(1):41-5. PubMed ID: 16432592
[TBL] [Abstract][Full Text] [Related]
23. Ocular Pathogens and Antibiotic Sensitivity in Bacterial Keratitis Isolates at King Khaled Eye Specialist Hospital, 2011 to 2014.
Al-Dhaheri HS; Al-Tamimi MD; Khandekar RB; Khan M; Stone DU
Cornea; 2016 Jun; 35(6):789-94. PubMed ID: 27078003
[TBL] [Abstract][Full Text] [Related]
24. In vitro comparison of combination and monotherapy for the empiric and optimal coverage of bacterial keratitis based on incidence of infection.
Kowalski RP; Kowalski TA; Shanks RM; Romanowski EG; Karenchak LM; Mah FS
Cornea; 2013 Jun; 32(6):830-4. PubMed ID: 23132444
[TBL] [Abstract][Full Text] [Related]
25. Clinical resistance of Staphylococcus keratitis to ciprofloxacin monotherapy.
Sharma V; Sharma S; Garg P; Rao GN
Indian J Ophthalmol; 2004 Dec; 52(4):287-92. PubMed ID: 15693319
[TBL] [Abstract][Full Text] [Related]
26. Microbial keratitis in Waikato, New Zealand.
Pandita A; Murphy C
Clin Exp Ophthalmol; 2011 Jul; 39(5):393-7. PubMed ID: 21176039
[TBL] [Abstract][Full Text] [Related]
27. Minimum inhibitory concentrations of standard and novel antimicrobials for isolates from bacterial keratitis.
Sueke H; Kaye S; Neal T; Murphy C; Hall A; Whittaker D; Tuft S; Parry C
Invest Ophthalmol Vis Sci; 2010 May; 51(5):2519-24. PubMed ID: 20019362
[TBL] [Abstract][Full Text] [Related]
28. Clinical Characteristics and Bacteriological Profile of Moraxella Keratitis.
Inoue H; Suzuki T; Inoue T; Hattori T; Nejima R; Todokoro D; Hoshi S; Eguchi H; Miyamoto H; Ohashi Y
Cornea; 2015 Sep; 34(9):1105-9. PubMed ID: 25970435
[TBL] [Abstract][Full Text] [Related]
29. Risk factors, microbiological profile, and treatment outcomes of pediatric microbial keratitis in a tertiary care hospital in Hong Kong.
Young AL; Leung KS; Tsim N; Hui M; Jhanji V
Am J Ophthalmol; 2013 Nov; 156(5):1040-1044.e2. PubMed ID: 23972308
[TBL] [Abstract][Full Text] [Related]
30. Fourth-generation fluoroquinolone-resistant bacterial keratitis after refractive surgery.
Moshirfar M; Mirzaian G; Feiz V; Kang PC
J Cataract Refract Surg; 2006 Mar; 32(3):515-8. PubMed ID: 16631067
[TBL] [Abstract][Full Text] [Related]
31. BACTERIOLOGY AND RISK FACTORS OF BACTERIAL KERATITIS IN JIMMA, SOUTHWEST ETHIOPIA.
Gebremariam TT
Ethiop Med J; 2015 Oct; 53(4):191-7. PubMed ID: 27182585
[TBL] [Abstract][Full Text] [Related]
32. Surveillance of the Activity of Aminoglycosides and Fluoroquinolones Against Ophthalmic Pathogens from Europe in 2010-2011.
Sanfilippo CM; Morrissey I; Janes R; Morris TW
Curr Eye Res; 2016 May; 41(5):581-9. PubMed ID: 26200173
[TBL] [Abstract][Full Text] [Related]
33. Influence of fluoroquinolone susceptibility on the therapeutic response of fluoroquinolone-treated bacterial keratitis.
Wilhelmus KR; Abshire RL; Schlech BA
Arch Ophthalmol; 2003 Sep; 121(9):1229-33. PubMed ID: 12963604
[TBL] [Abstract][Full Text] [Related]
34. Profile of sight-threatening infectious keratitis: a prospective study.
Otri AM; Fares U; Al-Aqaba MA; Miri A; Faraj LA; Said DG; Maharajan S; Dua HS
Acta Ophthalmol; 2013 Nov; 91(7):643-51. PubMed ID: 22863376
[TBL] [Abstract][Full Text] [Related]
35. Treatment of experimental bacterial keratitis with topical trovafloxacin.
Barequet IS; Denton P; Osterhout GJ; Tuli S; O'Brien TP
Arch Ophthalmol; 2004 Jan; 122(1):65-9. PubMed ID: 14718297
[TBL] [Abstract][Full Text] [Related]
36. [Antibiotic susceptibility patterns of bacteria isolated from keratitis and intraocular infections at Fundación Oftalmológica de Santander (FOSCAL), Floridablanca, Colombia].
Galvis V; Tello A; Guerra A; Acuña MF; Villarreal D
Biomedica; 2014 Apr; 34 Suppl 1():23-33. PubMed ID: 24968033
[TBL] [Abstract][Full Text] [Related]
37. Bacterial susceptibility to topical antimicrobials and clinical outcome in bacterial keratitis.
Kaye S; Tuft S; Neal T; Tole D; Leeming J; Figueiredo F; Armstrong M; McDonnell P; Tullo A; Parry C
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):362-8. PubMed ID: 19684005
[TBL] [Abstract][Full Text] [Related]
38. Microbial keratitis in los angeles: the doheny eye institute and the los angeles county hospital experience.
Sand D; She R; Shulman IA; Chen DS; Schur M; Hsu HY
Ophthalmology; 2015 May; 122(5):918-24. PubMed ID: 25600200
[TBL] [Abstract][Full Text] [Related]
39. Clinical Features, Antibiotic Susceptibility Profile, and Outcomes of Infectious Keratitis Caused by Stenotrophomonas maltophilia.
Palioura S; Gibbons A; Miller D; OʼBrien TP; Alfonso EC; Spierer O
Cornea; 2018 Mar; 37(3):326-330. PubMed ID: 29408828
[TBL] [Abstract][Full Text] [Related]
40. Trends in Microbiological and Antibiotic Sensitivity Patterns in Infectious Keratitis: 10-Year Experience in Mexico City.
Hernandez-Camarena JC; Graue-Hernandez EO; Ortiz-Casas M; Ramirez-Miranda A; Navas A; Pedro-Aguilar L; Lopez-Espinosa NL; Gaona-Juarez C; Bautista-Hernandez LA; Bautista-de Lucio VM
Cornea; 2015 Jul; 34(7):778-85. PubMed ID: 25811724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
